Platelet transfusions: Utilization and associated costs in a tertiary care hospital

American Journal of Hematology

Volumn 64, Issue 4, 2000, Pages 251-256

  Meehan, K R ^a,c   Matias, C O ^a   Rathore, S S ^a   Sandler, S G ^a   Kallich, J ^b   LaBrecque, J ^b   Erder, H ^b   Schulman, K A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b AMGEN INC   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Alloimmunization; Costs; Platelets; Resource use; Transfusion trigger

Indexed keywords

ADULT; ARTICLE; BLOOD DONOR; COST UTILITY ANALYSIS; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESOURCE ALLOCATION; THROMBOCYTE TRANSFUSION;

ADULT; COSTS AND COST ANALYSIS; FEMALE; HOSPITALS; HUMAN; MALE; MIDDLE AGE; PLATELET TRANSFUSION; PROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T;

EID: 0033854896     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-8652(200008)64:4<251::AID-AJH3>3.0.CO;2-N     Document Type: Article

References (35)

1. Collection and transfusion of blood in the United States 1982-1992
2. Collection and transfusion of blood and blood components in the United States 1992
3. Blood transfusion options: Improving outcomes and reducing costs
4. Platelet transfusion therapy
5. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets
6. Guidelines for platelet transfusions
7. Practice guidelines for blood component therapy
8. Platelet Transfusion Guidelines
9. Guidelines for platelet transfusions
10. Establishing practice guidelines for surgical blood management
11. Controversies in transfusion medicine: Prophylactic platelet transfusion revisited after 25 years
12. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients
13. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets
14. The trial to reduce alloimmunization to platelets study group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions
15. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs
16. A survey of blood component use in a German university hospital
17. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions
18. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin
19. Thrombopoietin
20. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation
21. Platelet utilization in a university hospital
22. Epidemiology and cost analysis of platelet transfusions at a tertiary care medical center
23. Clinical factors influencing post-transfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation: A prospective analysis
24. Alloimmune refractoriness to platelet transfusions
25. Providing platelets for refractory patients: Prudent strategies
26. Randomized study of prophylactic platelet transfusions threshold during induction therapy for adult acute leukemia: 10,000/μl versus 20,000/μl
27. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia
28. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia
29. Lowering the threshold for prophylactic platelet transfusion: Is the risk of bleeding increased?
30. Platelet transfusions: The 20,000/μl trigger
31. Clinical results of a stringent policy on prophylactic platelet transfusion: Non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution
32. Blood transfusion costs: A multicenter study
33. Computer-assisted audits of blood component transfusion
34. Clinical factors influencing the efficacy of pooled platelet transfusions